Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024
IK-595 first cohort treated and cleared safety evaluation window
Related news for (IKNA)
- Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
- 24/7 Market News Snapshot 15 July, 2025 – Ikena Oncology, Inc. Common Stock (NASDAQ:IKNA)
- Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
- 24/7 Market News Snapshot 23 December, 2024 – Ikena Oncology, Inc. Common Stock (NASDAQ:IKNA)
- Ikena Oncology Discontinues Clinical IK-930 Program